Therios 75

Main information

  • Trade name:
  • Therios 75
  • Pharmaceutical form:
  • Tablet
  • Medicine domain:
  • Animals
  • Medicine type:
  • Allopathic drug

Documents

Localization

  • Available in:
  • Therios 75
    Romania
  • Language:
  • English

Therapeutic information

  • Therapeutic group:
  • Cefalexin
  • Therapeutic area:
  • Dogs

Other information

Status

  • Source:
  • HMA - Europe
  • Authorization number:
  • FR/V/0213/001
  • Authorization date:
  • 09-06-2011
  • EU code:
  • FR/V/0213/001
  • Last update:
  • 09-08-2016

Summary of Product characteristics: dosage,interactions,side effects

VeterinaryMedicinalProduct

Therios75mgChewableTabletsforCats

PARTIB

SUMMARYOFTHEPRODUCT

CHARACTERISTICS

PharmaceuticalForm

ChewableTablet

1. NAMEOFTHEVETERINARYMEDICINALPRODUCT

Therios75mgChewableTabletsforCats

2. QUALITATIVEANDQUANTITATIVECOMPOSITION

Each250mgtabletcontains

Activesubstance:

Cefalexin(ascefalexinmonohydrate)...........................................75mg

Excipient(s):

Forafulllistofexcipients,seesection6.1.

3. PHARMACEUTICALFORM

Chewabletablet

Oblongscoredbeigetablet.Thetabletscanbedividedintoequalhalves

4. CLINICALPARTICULARS

4.1Targetspecies

Cats

4.2Indicationsforuse,specifyingthetargetspecies

Incats:

Infectionscausedbybacteriasusceptibletocefalexin

.LowerurinarytractinfectionsduetoE.coliandProteusmirabilis,

.Treatmentofcutaneousandsubcutaneousinfections:pyodermaduetoStaphylococcus.spp

andwoundsandabscessesduetoPasteurellaspp.

4.3Contraindications

Donotuseincaseofseverekidneyfailure

Donotuseinanimalswhichareknowntobehypersensitivetocephalosporinsoranyother

substancefromthe 

-lactamgroup.

Donotuseinrabbits,guineapigs,hamstersandgerbilsandothersmallrodents.

Theproductiscontra-indicatedincaseofaknownresistancetocefalexin.

4.4Specialwarningsforeachtargetspecies

None

4.5Specialprecautionsforuse

i)Specialprecautionsforuseinanimals

Aswithotherantibioticswhichareexcretedmainlybythekidneys,unnecessaryaccumulation

mayoccurinthebodywhenrenalfunctionisimpaired.Incasesofknownrenalinsufficiency,

thedoseshouldbereducedand/ortheintervalofadministrationincreased andnephrotoxic

drugsshouldnotbeadministeredconcurrently.

Whereverpossible,theuseoftheproductshouldbebasedonsusceptibilitytesting.

Officialandlocalantimicrobialpoliciesonantibiotherapyshouldbetakenintoaccountwhen

theproductisused.

UseoftheproductdeviatingfromtheinstructionsgivenintheSPCmayincreasethe

prevalenceofbacteriaresistanttothecefalexinandmaydecreasetheeffectivenessof

treatmentwithpenicillinsduetothepotentialforcrossresistance.

Thisproductshouldnotbeusedtotreatkittenslessthan9weeksofage.

Useoftheproductincatsweighinglessthan2.5kgshouldbeinaccordancewiththe

benefit/riskassessmentperformedbytheresponsibleveterinarian.

ii)Specialprecautionstobetakenbythepersonadministeringtheveterinary

medicinalproducttoanimals

Cephalosporinsmaycausesensitisation(allergy)followinginjection,inhalation,ingestionor

skincontact.Sensitivitytopenicillinsmayleadtocrosssensitivitytocephalosporinsandvice

versa.Allergicreactionstothesesubstancesmayoccasionallybeserious.

Donothandlethisproductifyouknowyouaresensitised,orifyouhavebeen

advisednottoworkwithsuchpreparations.

Handlethisproductwithgreatcaretoavoidexposuretakingallrecommended

precautions.Washhandsafteruse.

Ifyoudevelopsymptomsfollowingexposure,suchasskinrash,youshould

seekmedicaladviceandshowthedoctorthiswarning.Swellingoftheface,lips

oreyesordifficultyinbreathingaremoreserioussymptomsandrequireurgent

medicalattention.

Incaseofaccidentalingestion,seekmedicalattentionandshowthepackage

leafletorthelabeltothedoctor.

4.6Adversereactions(frequencyandseriousness)

Vomitingand/ordiarrhoeahavebeenobservedincats.Incaseofrecurringvomitingand/or

diarrhoea,thetreatmentshouldbediscontinuedandtheadviceoftheattendingveterinarian

sought.

Allergicreactionsarepossiblewithcefalexinandallergiccross- reactivitywithotherβ-lactams

mayoccur..

4.7 Useduringpregnancy,lactationorlay

Laboratorystudiesinmouse,ratandrabbithavenotproducedanyevidenceofteratogenic

effects.Thesafetyoftheproducthasnotbeeninvestigatedinpregnantorlactatingcatsand

shouldonlybeusedaccordingtothebenefit/riskassessmentbytheresponsibleveterinarian.

4.8Interactionwithothermedicinalproductsandotherformsofinteraction

Thebactericidalactivityofcephalosporinsisreducedbyconcomitantadministrationof

bacteriostaticactingcompounds(macrolides,sulfonamidesandtetracyclines).

Nephrotoxicitycanbeincreasedwhen1 st

generationcephalosporinsarecombinedwith

polypeptideantibiotics,aminoglycosidesorsomediuretics(furosemide).

Concomitantusewithsuchactivesubstancesshouldbeavoided.

4.9Amountstobeadministeredandadministrationroute

Oraluse.

15mgcefalexinperkgbodyweighttwicedaily,equivalentto1tabletfor5kgbodyweightfor:

-5daysforwoundsandabscesses

-10to14daysincaseofurinarytractinfections,

-14daysatleastincaseofpyoderma.Thetreatmentmustbecontinuedfor10daysonce

thelesionshavedisappeared.

Toensureacorrectdosagebodyweightshouldbedeterminedasaccuratelyaspossibleto

avoidunderdosing

Incaseofuseofhalftablets, puttheremainingquantityofthetabletbackintotheblister

pocketanduseitforthenextadministration.

Thetabletsareflavoured.Theycanbeadministeredwithfoodordirectlyintothemouthofthe

animal.

4.10Overdose(symptoms,emergencyprocedures,antidotes),ifnecessary

Notapplicable

4.11Withdrawalperiod(s)

Notapplicable.

5. PHARMACOLOGICALPROPERTIES

Cefalexinmonohydrateisabactericidalantibioticofthecephalosporinfamily,obtainedby

hemi-synthesisofthe7-aminocephalosporanicnucleus.

Pharmacotherapeuticgroup:Antibacterialforsystemicuse,first-generationcephalosporin

ATCvetcode:QJ01DB01

5.1Pharmacodynamicproperties

Cefalexinactsbyinhibitingthenucleopeptidesynthesisofthebacterialwall.Cephalosporins

interferewithtranspeptidationbyacylatingtheenzymemakingitunabletocross-linkmuramic

acid-containingpeptidoglycanstrands.Theinhibitionofthebiosynthesisofthematerial

requiredtobuildthecellwallresultsinadefectivecellwallandconsequentlyosmotically

unstabletoprotoplasts.Thecombinedactionresultsincelllysisandfilamentformation.

CefalexinisactiveagainstGrampositiveandGramnegativebacteriasuchas

Staphylococcusspp(includingpenicillin-resistantstrains),Streptococcusspp.,and

EscherichiaColi.Cefalexinisnotinactivatedbyβ-lactamasesproducedbyGrampositive

bacteria.However,beta-lactamasesproducedbygram-negativebacteriacaninhibitcefalexin

byhydrolysisofthebeta-lactamcycle.

Resistancetocefalexinmaybeduetooneofthefollowingmechanismsofresistance.Firstly,

theproductionofvariousbeta-lactamases(cephalosporinase),thatinactivatetheantibiotic,is

themostprevalentmechanismamonggram-negativebacteria.Secondly,adecreasedaffinity

ofthePBPs(penicillin-bindingproteins)forbeta-lactamdrugsisfrequentlyinvolvedforbeta-

lactamresistantgram-positivebacteria.Lastly,effluxpumps,extrudingtheantibioticfromthe

bacterialcell,andstructuralchangesinporins,reducingpassivediffusionofthedrugthrough

thecellwall,maycontributetoimprovetheresistantphenotypeofabacterium.

Well-knowncross-resistance(involvingthesameresistancemechanism)existsbetween

antibioticsbelongingtothebeta-lactamgroupduetostructuralsimilarities.Itoccurswithb-

lactamasesenzymes,structuralchangesinporinsorvariationsineffluxpumps.Co-

resistance(differentresistancemechanismsinvolved)hasbeendescribedinE.coliduetoa

plasmidharbouringvariousresistancegenes.

5.2Pharmacokineticparticulars

Incats,thebioavailabilityafteroraladministrationisaround56%.

Incats,afterasingleoraladministrationof18.5mg/kgofcefalexin,theplasmaticpeakwas

reachedafter1.6hwithaconcentrationof22µg/ml.

Cefalexinwasdetectedinplasmatill24hoursafteradministration.

Thediffusionofcefalexinintissueishigh.Cefalexinismainlyeliminatedbyurinaryroute

(85%)underactiveform,urinaryconcentrationpeaksaresignificantlyhigherthanplasmatic

concentrationpeaks.

Environmentalproperties

Notapplicable

6. PHARMACEUTICALPARTICULARS

6.1Listofexcipients

Pigliverpowder

Yeast

Croscarmellosesodium

Magnesiumstearate

Anhydrouscolloidalsilica

Calciumhydrogenphosphatedihydrate

6.2Incompatibilities

None

6.3Shelflife

Shelf-lifeoftheveterinarymedicinalproductaspackagedforsale:

Polyvinylchloride/thermo-elast/polyvinylidenechloride –aluminiumheatsealedblister: 3years

Polyamide/aluminium/polyvinylchloride –aluminiumheatsealedblister:30months

Anydividedtabletportionsremainingafter24hoursshouldbediscarded

6.4.Specialprecautionsforstorage

Donotstoreabove25°C

Storeintheoriginalpackage

Returnanyhalvedtablettotheopenedblisterpack

6.5Natureandcompositionofimmediatepackaging

Blister:

Polyvinylchloride/thermo-elast/polyvinylidenechloride –aluminiumheatsealed

containing10tabletsperblister

Polyamide/aluminium/polyvinylchloride –aluminiumheatsealedcontaining10

tabletsperblister

Cardboardboxwith1blisterof10tablets

Cardboardboxwith2blistersof10tablets

Cardboardboxwith10blistersof10tablets

Cardboardboxwith15blistersof10tablets

Cardboardboxwith20blistersof10tablets

Notallpacksizesmaybemarketed.

6.6Specialprecautionsforthedisposalofunusedveterinarymedicinalproductor

wastematerialsderivedfromtheuseofsuchproducts

Anyunusedveterinarymedicinalproductorwastematerialsderivedfromsuchveterinary

medicinalproductshouldbedisposedofinaccordancewithlocalrequirements.

7. MARKETINGAUTHORISATIONHOLDER

LaboratoiresSOGEVAL

200avenuedeMayenne,BP2227

53022LAVALCedex9

France

Tel:33.2.43.49.51.51

Fax:33.2.43.53.97.00

E-mail: sogeval@sogeval.fr

8. MARKETINGAUTHORISATIONNUMBER(S)

9. DATEOFFIRSTAUTHORISATION/RENEWALOFTHEAUTHORISATION

10 DATEOFREVISIONOFTHETEXT

PROHIBITIONOFSALE,SUPPLYAND/ORUSE

Tobecompletedinaccordancewithnationalrequirements

24-11-2018

Blokhuis: 1,25 miljoen euro voor educatie Tweede Wereldoorlog

Blokhuis: 1,25 miljoen euro voor educatie Tweede Wereldoorlog

Staatssecretaris Paul Blokhuis van Volksgezondheid, Welzijn en Sport heeft 1,25 miljoen euro beschikbaar gesteld voor educatieprojecten over de Tweede Wereldoorlog. In 2019 en 2020 vieren we dat Nederland 75 jaar is bevrijd, eerst het zuidelijke deel in 1944 en daarna de rest van Nederland en Nederlands-Indië in 1945. Dit lustrumjaar wordt de bevrijding nog groter gevierd dan anders en wordt er extra nadruk gelegd op het herinneren van de oorlog. De 1,25 miljoen euro komt boven op de 3,5 miljoen voor ond...

Netherlands - Ministerie van Volksgezondheid, Welzijn en Sport

21-11-2018

FDA approves new treatment for patients with acute myeloid leukemia

FDA approves new treatment for patients with acute myeloid leukemia

The FDA approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adults who are 75 years of age or older or who have other chronic health conditions or diseases (comorbidities) that may preclude the use of intensive chemotherapy.

FDA - U.S. Food and Drug Administration

30-10-2018

Sciegen Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Irbesartan Tablets, USP  75 Mg, 150 Mg, and 300 Mg Due to The Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in The Active Pharmaceutical Ingredient (API)

Sciegen Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Irbesartan Tablets, USP 75 Mg, 150 Mg, and 300 Mg Due to The Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in The Active Pharmaceutical Ingredient (API)

ScieGen Pharmaceuticals, Inc. is voluntarily recalling listed lots, within expiry, of Irbesartan Tablets, USP 75 mg, 150 mg, and 300 mg dosage forms to the consumer level. These products are being recalled due to the presence of an impurity, N-nitrosodiethylamine (NDEA) contained in the API Irbesartan, USP manufactured by Aurobindo Pharma Limited. This impurity, which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, has been classified as a...

FDA - U.S. Food and Drug Administration

1-10-2018

Public Notification: FX75000 contains hidden drug ingredient

Public Notification: FX75000 contains hidden drug ingredient

The Food and Drug Administration is advising consumers not to purchase or use FX75000, a product promoted for sexual enhancement. This product was identified during an examination of international mail shipments.

FDA - U.S. Food and Drug Administration

28-9-2018

Endo Pharmaceuticals Issues Voluntary Nationwide Recall for Two Lots of Robaxin® 750mg Tablets 100 Count Bottle Packs Due to Incorrect Daily Dosing Information on Label

Endo Pharmaceuticals Issues Voluntary Nationwide Recall for Two Lots of Robaxin® 750mg Tablets 100 Count Bottle Packs Due to Incorrect Daily Dosing Information on Label

Endo International plc (NASDAQ: ENDP) today announced that one of its operating companies, Endo Pharmaceuticals Inc., is voluntarily recalling two lots of Robaxin® (methocarbamol tablets, USP) 750mg Tablets 100 Count Bottle pack to the consumer level. The products have been found to have incorrect daily dosing information on the label due to a labeling error which misstates the daily dose as "two to four tablets four times daily" rather than the correct dosage of "two tablets three times daily." (see pic...

FDA - U.S. Food and Drug Administration

21-7-2018

Allergy Alert for Undeclared Milk in Food Lion Brand Dill Pickle Flavored Potato Chips

Allergy Alert for Undeclared Milk in Food Lion Brand Dill Pickle Flavored Potato Chips

Shearer’s Foods, LLC of Massillon, OH is recalling Food Lion brand 7.75 ounce packages of Dill Pickle Flavored Potato Chips because they may contain undeclared milk. People who have an allergy or severe sensitivity to milk run the risk of serious or life-threatening allergic reaction if they consume this product. The recalled Dill Pickle Flavored Potato Chips were distributed to Food Lion stores in NC, SC, GA, PA, KY, VA, TN, DE, MD, and WV between Dec 1st, 2017 and July 19, 2018.

FDA - U.S. Food and Drug Administration

7-10-2016

Experts for the European Pharmacopoeia's groups of experts and working parties

Experts for the European Pharmacopoeia's groups of experts and working parties

A very large part of the work related to the drafting of new monographs for the European Pharmacopoeia (EDQM) is carried out by external experts in 75 groups of experts and working parties. Experts for the groups are appointed for a period of three years, and the EDQM is now seeking experts for the period from 2017 to 2019.

Danish Medicines Agency

24-9-2018

Ovitrelle (Merck Europe B.V.)

Ovitrelle (Merck Europe B.V.)

Ovitrelle (Active substance: Choriogonadotrophin alfa) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)6220 of Mon, 24 Sep 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/320/T/75

Europe -DG Health and Food Safety

11-6-2018

Isentress (Merck Sharp and Dohme B.V.)

Isentress (Merck Sharp and Dohme B.V.)

Isentress (Active substance: raltegravir) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)3767 of Mon, 11 Jun 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/860/T/75

Europe -DG Health and Food Safety